

Receipt

AUG 13 2001

**TRANSMITTAL LETTER**  
**(General - Patent Pending)**

Docket No.  
021286/027 8719

In Re Application Of:  
Nobuaki Takahashi, et al.

Serial No.  
09/811,367

Filing Date  
March 16, 2001

Examiner  
NYA

Group Art Unit  
NYA

Title: **SOLUBLE MAST CELL FUNCTION ASSOCIATED ANTIGEN (MAFA) PHARMACEUTICAL  
COMPOSITIONS AND METHODS OF MAKING AND USING THEM**

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Transmitted herewith is:

Request for Corrected Filing Receipt  
Copy of Filing Receipt  
Reply Postcard

**RECEIVED**  
NOV 19 2001  
**TC 1700**

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Commissioner is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

  
Signature

Dated: August 9, 2001

John R. Wetherell, Jr.  
Reg. N . 31,678

I certify that this document and fee is being deposited  
on August 9, 2001 with the U.S. Postal Service as  
first class mail under 37 C.F.R. 1.8 and is addressed to the  
Commissioner of Patents and Trademarks, Washington,  
D.C. 20231.




Signature of Person Mailing Correspondence

Linda Anders

Typed or Printed Name of Person Mailing Correspondence

cc: San Francisco Docketing  
Rene Prom



Atty Dkt No. 021286/027 8719

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Nobuaki Takahashi, et al. )  
Serial No. 09/811,367 )  
Filed: March 16, 2001 )  
For: SOLUBLE MAST CELL )  
FUNCTION ASSOCIATED )  
ANTIGEN (MAFA) )  
PHARMACEUTICAL )  
COMPOSITIONS AND METHODS )  
OF MAKING AND USING THEM )

I hereby certify that this paper and the attached  
papers are being deposited with the United States  
Postal Service as first class mail in an envelope  
addressed to:  
Office of Initial Patent Examination  
Customer Service Center  
Commissioner for Patents  
Washington, DC 20231, on this date

8-9-01  
Date

*Linda Anders*  
LINDA ANDERS

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents  
Washington, D.C. 20231  
ATTN: Office of Initial Patent Examination Customer Service Center

**RECEIVED**  
NOV 19 2001  
TC 1700

Sir:

After careful review of the Filing Receipt, an error has been noted. It is requested that this error be corrected so that the Filing Receipt reads as set forth below, and that Applicant be provided with a corrected Filing Receipt.

Under TITLE:

Please insert -- Soluble -- to the beginning of the title.

A red-lined copy of the Filing Receipt is attached hereto. Applicant respectfully requests correction of the Filing Receipt and reissuance of the same.


Respectfully submitted,

PILLSBURY WINTHROP LLP

By: *John R. Wetherell, Jr.*  
John R. Wetherell, Jr.  
Registration No. 31,678

Dated: August 9, 2001

Address all correspondence to:  
50 Fremont Street  
San Francisco, CA 94105-2228  
Tel: (858) 509-4065  
Fax: (415) 983-1200



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/811,367	03/16/2001	1645	2138	021286/027 8719	5	61	10

CONFIRMATION NO. 6403

Robert M. Bedgood  
5th Floor  
50 Fremont Street  
San Francisco, CA 94105-2230

RECEIVED

AUG 07 2001

PILLSBURY WINTHROP LLP/SF

FILING RECEIPT



\*C600000006366878\*

NOV 19 2001

TC 1700

Date Mailed: 08/01/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Nobuaki Takahashi, Solana Beach, CA;  
Toshifumi Mikayama, San Diego, CA;

## Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/190,716 03/17/2000

## Foreign Applications

If Required, Foreign Filing License Granted 05/31/2001

Projected Publication Date: 11/08/2001

N n-Publication Request: No

Early Publication Request: No

## Title

Soluble Mast cell function associated antigen (MAFA) pharmaceutical compositions and methods of making and using them

## Preliminary Class

435

---

**Data entry by :** MOHAMED, RIZAHA

**Team :** OIPE

**Date:** 08/01/2001





**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**RECEIVED**

NOV 19 2001

**GRANTED**

**TC 1700**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
 Office of Initial Patent Examination  
 Customer Service Center  
 Washington, DC 20231